Replies to post #85086 on Ayala Pharmaceuticals Inc (fka ADXS)

[Chemist823]

Could be re-occurrence #'s, they probably know how many patients experienced re-occurrence and when compared to historical may show some improvement.

[cdiddy01]

Well said. I can understand that.

However, I do hope this "smidgen" of rational, based on blended data that the trial is not failing, isn't the main impetus behind continuing the funding of it. Cutting it for cash reasons made sense to me and now that's no longer the case.

I'm still hoping Blue is right in that the reason ADXS is continuing the trial, along with the potential changes, is to accelerate the process of securing a partner who will eventually take it over.

I suppose you combine that with your statement and I guess we could have something.

[oakrock]

Somebody knows something and there is A reason, it is not being abandoned which must be positive...hint hint ??

[fbg0316]

Locking in $100 million upfront in exchange for less on the back end would be preferable to another dilution on unfavorable terms.